Connecting Genomic Research and Manufacturing into a Single Industrial Network

Saudi Arabia is connecting genomic analysis, clinical trials, and Good Manufacturing Practice (GMP) production domestically under its 2024 National Biotechnology Strategy. Lifera, established in 2023 by the Public Investment Fund (PIF), serves as a Contract Development and Manufacturing Organization (CDMO) in this framework, while the King Abdullah International Medical Research Center (KAIMRC) conducts whole-genome and exome analysis, CRISPR design, and stem cell and organoid research. The strategic collaboration between the King Faisal Specialist Hospital and Research Center (KFSHRC) and Lifera focuses on building infrastructure and expertise for cell and gene therapies. This represents an industrial policy aimed at transforming a market reliant on imported therapies into a self-sustaining bio-ecosystem of research, clinical development, and manufacturing.

CD19 CAR-T is the First Validation of Local Clinical Implementation

The Saudi Food and Drug Authority (SFDA) approved a Phase 1 clinical trial for autologous CD19 chimeric antigen receptor T-cell (CAR-T) therapy for adult patients with relapsed or refractory CD19-positive acute lymphoblastic leukemia (ALL) on August 28, 2025. This unbranded investigational therapy modifies patient T-cells using a closed lentiviral vector system targeting CD19. KFSHRC has completed the first patient dosing and local production. The manufacturing time has been reduced from 28 days for overseas production to 12–14 days, and the cost per patient has dropped from 1.3 million Saudi riyals to approximately 250,000 Saudi riyals. The hospital aims to produce 100 cases annually. Commercial competitors include Novartis (NVS)'s Kymriah (tisagenlecleucel, CD19) and Gilead Sciences (GILD)'s Tecartus (brexucabtagene autoleucel, CD19), while non-cellular therapy standards include Amgen (AMGN)'s Blincyto (blinatumomab, CD19×CD3) and Pfizer (PFE)'s Besponsa (inotuzumab ozogamicin, CD22).

CRISPR Implementation Has Already Reached Clinical Application

The Saudi Ministry of National Guard Health Affairs (MNGHA) administered Casgevy (exagamglogene autotemcel) to a transfusion-dependent beta-thalassemia patient outside of a clinical trial setting. Developed by Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP), Casgevy is an approved therapy that edits the BCL11A erythroid enhancer in autologous hematopoietic stem cells using CRISPR-Cas9 to restore fetal hemoglobin production. The U.S. FDA approved it for sickle cell disease on December 8, 2023, and for transfusion-dependent beta-thalassemia on January 16, 2024. The European Union Executive Commission granted conditional marketing authorization on February 12, 2024. Saudi Arabia's challenge is to expand this treatment experience into in-house editing technology, vector production, and commercial-scale manufacturing capabilities.

Early Production Contracts Form the Foundation of Advanced Therapy Supply Chains

Lifera's subsidiary, SaudiBio, has entered into a multi-year agreement with Novo Nordisk (NVO) to perform insulin formulation, filling, and finishing at Sudair, planning to supply over 50% of Saudi demand starting in 2028. KAUST's vaccine and protein therapy facility, along with SPIMACO (2070.SR) and CanSinoBio (6185.HK)'s MCV4 meningococcal vaccine localization, are also part of this phased manufacturing strategy. At the 2024 Riyadh Global Medical Biotechnology Summit, contracts exceeding $100 million were signed, with 59 deals closed over three cumulative events, including partnerships with Pfizer, AstraZeneca (AZN), and Novo Nordisk. The Saudi cell and gene therapy market is projected to grow from $234.5 million in 2025 to $1.0263 billion in 2034, making local manufacturing crucial not only for cost reduction but also for building a regional export-oriented CDMO.